Navigation Links
Anti-cancer gene discovered: Perspective for therapy
Date:2/24/2009

Starting with the tiny fruit fly, and then moving into mouse and human patients, researchers at VIB connected to the Center for Human Genetics (K.U. Leuven) showed that the same gene suppresses cancer in all three. Reciprocally, switching off the gene leads to cancer. The scientists think there is a good chance that the gene can be switched on again with a drug. They report their findings in the reputed scientific journal PLoS Biology.

Specialized cells

All of us begin our lives as one cell, which divides into two, four, eight into a human of a few billion cells. Almost all cells in an adult human skin cells, liver cells, eye lens cells, nerve cells, insulin-producing cells etc are highly specialized to perform a specific function. They are no longer capable of taking on another task: when a skin cell divides, you get more skin cells. During the growth from an embryo to an adult human, the cells become more and more specialized ("differentiated", biologists say).

Cancer cells are an exception to that rule: they are much less specialized, and feel at home in different places in the body. Researchers have long believed that cells must take the last step in their specialization to be better protected from turning into cancer cells. However, this was not proven in a living organism.

Suppressing cancer

Wouter Bossuyt from the Group of Bassem Hassan and their fellow VIB researchers at K.U.Leuven, now demonstrate with fruit flies that master control genes steering the specialization step indeed inhibit tumor formation. The specific example the VIB scientists used, are the ones biologists call the Atonal genes. These genes are very similar to each other in all species, from flies to humans.

With mice, and in collaboration with colleagues from the United States, they showed that loss of one of those genes, Atonal homolog 1 or ATOH1, causes colon cancer. The gene regulates the last step in the specialization to epithelial cell of the colon. Humans with colon cancer frequently have an inactivated ATOH1 gene, the researchers observed.

Treatment

The researchers could in a test tube reactivate the gene in human colon cancer cells. The tumor cells stopped growing and committed suicide. Since they were able to switch the gene on with a reasonably simple chemical, this opens possibilities to one day perhaps switch the gene back on in living patients. It will be very important in the future to study in detail how exactly ATOH1 does performs its anti-cancer job


'/>"/>

Contact: Sooike Stoops
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology technology :

1. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
2. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. Computer predicts anti-cancer molecules
5. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
6. ARIUS presents new findings for anti-cancer antibody programs at AACR
7. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
8. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. Egenix Licenses Harvard Anti-Cancer Platform
11. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... SAN DIEGO , March 29, 2017 /PRNewswire/ ... developing novel oncology and drug-delivery therapies, today announced ... U.S. Food and Drug Administration voted 11 to ... (under the skin) injection was favorable for patients ... large B-cell lymphoma and chronic lymphocytic leukemia. The ...
(Date:3/29/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Agricultural Chelates ... over the next decade to reach approximately $825.4 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/29/2017)... , March 29, 2017 The Global Microfluidic ... report is a specialized and comprehensive study on the existing state ... America , Europe and ... Middle East and Africa . ... Browse 172 Tables and ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... on March 22 in Philadelphia. The event was offered by the Chamber of ... Roundtable featured breakout groups and interaction with speakers who are leaders in ...
Breaking Biology Technology:
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):